Zeaxanthin
drug drugOn this page
Also known as African marigold flowerAnchovyxanthinAztec marigold flowerAztec marigold zeaxanthin extractBig marigold flowerE 161HE-161H(I)INS NO.161H(I)INS-161H(I)LuteinoftaOptisharpTagetes erecta flowerTagetes ernstii flowerTagetes excelsa flowerTagetes heterocarpha flowerTagetes major flowerTagetes patula flowerTagetes remotiflora flowerXanthophyll 3Zeagold
Summary
Zeaxanthin (CHEMBL2359248) is a phase-3 clinical-stage small-molecule cofactor; indicated across 2 conditions including neoplasm and glaucoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 2 conditions
- Clinical trials: 14
- Chemistry: 568.9 Da · C40H56O2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2359248 |
| Name | Zeaxanthin |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 5280899 |
| ChEBI | CHEBI:27547 |
| Molecular formula | C40H56O2 |
| Molecular weight | 568.9 |
| InChIKey | JKQXZKUSFCKOGQ-QAYBQHTQSA-N |
SMILES: CC1=C(C(C[C@@H](C1)O)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(C[C@H](CC2(C)C)O)C)\C)\C)/C)/C
IUPAC name: (1R)-4-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4R)-4-hydroxy-2,6,6-trimethylcyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-3,5,5-trimethylcyclohex-3-en-1-ol
Pharmacological roles (ChEBI): cofactor.
Other ChEBI roles (chemical / environmental): bacterial metabolite.
Also known as: African marigold flower, Anchovyxanthin, Aztec marigold flower, Aztec marigold zeaxanthin extract, Big marigold flower, E 161H, E-161H(I), INS NO.161H(I), INS-161H(I), Luteinofta, Optisharp, Tagetes erecta flower
Patent coverage: 9,050 distinct patent families (25,398 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 1 | MONDO:0005070 | MONDO:0004992 |
| glaucoma | 1 | MONDO:0005041 | MONDO:0005041 |
Clinical trials
Total trials: 14.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 9 |
| PHASE3 | 2 |
| PHASE2 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00345176 | PHASE3 | COMPLETED | Age-Related Eye Disease Study 2 (AREDS2) |
| NCT01621789 | PHASE3 | COMPLETED | Efficacy of Lutein, Zeaxanthine and Trypan Blue to Stain the Anterior Lens Capsule |
| NCT00596024 | PHASE2 | TERMINATED | Lutein and Alzheimer’s Disease Study |
| NCT01048476 | PHASE1/PHASE2 | UNKNOWN | Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration |
| NCT05232409 | PHASE1 | UNKNOWN | Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer |
| NCT00527553 | Not specified | COMPLETED | The Effect of Eggs and Egg Products on Macular Pigment |
| NCT00564902 | Not specified | COMPLETED | The Zeaxanthin and Visual Function Study |
| NCT00909090 | Not specified | COMPLETED | Macular Pigment and Glare Disability |
| NCT01354093 | Not specified | COMPLETED | The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel) |
| NCT01404845 | Not specified | COMPLETED | Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation |
| NCT01528605 | Not specified | COMPLETED | Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration |
| NCT02017418 | Not specified | COMPLETED | The Effects of a Zeaxanthin Intervention on Visuomotor Function |
| NCT02113254 | Not specified | TERMINATED | Study of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine |
| NCT06358352 | Not specified | COMPLETED | Clinical and Radiographic Assessment of PRF Versus Lutein Placement |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.